

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



杭州启明醫療器械股份有限公司
Venus Medtech (Hangzhou) Inc.

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2500)

**VOLUNTARY ANNOUNCEMENT
SHAREHOLDING INCREASE IN THE COMPANY BY
AN EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Venus Medtech (Hangzhou) Inc. (the “**Company**” or “**Venus Medtech**”) hereby informs shareholders of the Company (the “**Shareholders**”) and potential investors that Mr. Zhenjun Zi (“**Mr. Zi**”), acting as an executive Director and general manager of the Company, informed the Company that, on June 9, 2023 and June 12, 2023, he had purchased an aggregate number of 446,500 shares of the Company through the open market for a total consideration of approximately HK\$2.98 million, upon which his shareholding in the Company increased to approximately 12.00%. The share purchases were not conducted pursuant to a trade plan or proposal. The Board has been further notified by Mr. Zi that, in the future, the management personnel of the Company, including him, may further purchase shares of the Company from time to time on the open market at the then prevailing market price through legally permissible means, depending on market conditions and in accordance with applicable rules and regulations.

According to Mr. Zi: “The shares purchased would be held for medium-to long-term investment purposes. I am proud to be an executive of Venus Medtech, I remain fully confident in the Company’s strategy, execution and long-term prospects, and I will continue to commit myself to the Company’s future development.”

The Company will continue to uphold the strategy of globalization and innovation with a focus on treatment for structural heart diseases, expedite sales in the global market and speed up multi-centered clinical trials worldwide as we strive to reward our Shareholders for their support.

By Order of the Board
Venus Medtech (Hangzhou) Inc.
Min Frank Zeng
Chairman

Hangzhou, June 13, 2023

As at the date of this announcement, the executive Directors are Mr. Min Frank Zeng, Mr. Zhenjun Zi and Ms. Meirong Liu; the non-executive Director is Mr. Ao Zhang; and the independent non-executive Directors are Mr. Ting Yuk Anthony Wu, Mr. Wan Yee Joseph Lau and Mr. Chi Wai Suen.